Invitrogen and Signalomics Collaborate to Develop Nanotechnology-Based Approaches to Cancer Diagnostics
"Our technology allows us to label the signal molecules of a cell and then visualize cells with faulty signaling, such as cancer cells. This approach allows physicians and scientists to diagnose diseased tissue as well as design therapeutics targeted to the faulty signal transduction," explained Dr. Christoph Block, CEO of Signalomics GmbH. "Cooperating with a strong partner like Invitrogen will accelerate our development, allowing this important technology to reach patients faster."
“Our technology allows us to label the signal molecules of a cell and then visualize cells with faulty signaling, such as cancer cells. This approach allows physicians and scientists to diagnose diseased tissue as well as design therapeutics targeted to the faulty signal transduction”
Signalomics is developing a nanobiotechnology-based in vivo diagnostics platform by coupling designer proteins with fluorescent semiconductor crystals. These nanocrystal-protein conjugates, which are only a few millionths of a millimeter in size and are extremely photostable, can be targeted to faulty signaling proteins that are expressed in tumor tissue. Once introduced into a cell, they can be visualized by applying a laser light of a specific wavelength, which makes the nanocrystal-protein conjugates emit light in different colors. The colors of the light help to identify cells with faulty signal molecules and allow detection of single tumor cell in vivo.
"Invitrogen, with tools and products like Dynal magnetic beads, Caltag antibodies and Molecular Probes labeling technologies, has long been a leading enabler of the development of diagnostic products," said John "Kip" Miller, Invitrogen's Senior Vice President, Enabling Technologies. "We are always eager to participate in R&D programs that will push the envelope as far as molecular diagnostics are concerned, and this collaboration allows us to leverage the unique capabilities of our Quantum Dot nanocrystals in the pursuit of earlier cancer diagnosis.
Through this agreement, Signalomics is continuing the joint development and identification of novel nanobiotech diagnostic products that it began in 2004 in cooperation with the BioPixels business unit of BioCrystal Ltd. Invitrogen Corporation announced the acquisition of both the BioPixels business and Quantum Dot Corporation on October 6, 2005.
Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com.
The goal of Signalomics GmbH is to develop custom-designed therapeutics and theranostics for illnesses that result from errors in cellular signal transduction. This includes in particular the development of highly specific molecular imaging agents and medications for cancer indications. Signalomics provides innovative products and solutions for the pharmaceutical industry, biotech companies and academic institutions. Signalomics GmbH was established in 2003 as a Spin-Off of the University of Applied Sciences Munster, Germany. For more information, visit www.signalomics.com.
Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to, those regarding: 1) The collaboration will develop an imaging agent that can be used to identify colon carcinomas requiring surgical intervention; 2) Invitrogen's involvement in the project will accelerate Signalomics' development efforts and allow the technology to reach patients faster. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks: a) Goals and focus of the collaboration are subject to change as results are obtained; b) Invitrogen's involvement in the project may not have a significant effect on the pace of development for the new technology; as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.